Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients

Arquivos de neuro-psiquiatria
Charles Peter TilberyGiorge Ribeiro Kelian

Abstract

Since 1993 the Federal Drug Administration approved the use of immunomodulatory therapy in multiple sclerosis (MS), modifying the natural course of disease, as demonstrate our experience in treatment of MS patients at the MS Treatment Center (CATEM). To evaluate patient behavior using immunomodulatory therapy for a period of five years treatment. We selected 390 patients in CATEM with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) with relapses. At initial treatment 292 (61.5%) patients presented RRMS, 98 (20.6%) SPMS with relapses, 27 SPMS (5.6%) and 58 (12.1%) primary progressive MS (PPMS). In RRMS 182 (62.5%) used the interferon beta 1a SC, 15 (5.2%) interferon beta 1a IM, 85 (29%) interferon beta 1b and 10 (3.3%) glatiramer acetate. In SPMS 63 (64.3%) used interferon beta 1a SC, 4 (4.1%) interferon beta 1a IM and 31 (31.4%) interferon beta 1b. We observed that in this period 195 (50%) migrated between drugs, 35 (9%) gave up therapy and 160 (41%) continued the initial therapy. Stopping the immunomodulatory therapy emerges as a problem in the second year of treatment and it can be a subset of interferon non responsive or development of neutralizing antibodies.

References

Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Oct 9, 2001·Acta Neurologica Scandinavica·D CallegaroM Scaff
Apr 9, 2002·Multiple Sclerosis : Clinical and Laboratory Research·M S FreedmanUNKNOWN Paris Workshop Group
Feb 25, 2003·Lancet·Graziella FilippiniGeorge P A Rice
Dec 4, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A CarráL Rodríguez
Mar 1, 2005·Multiple Sclerosis : Clinical and Laboratory Research·K E T O'Rourke, M Hutchinson

❮ Previous
Next ❯

Citations

Apr 9, 2008·Arquivos de neuro-psiquiatria·Sergio Semeraro JordyMirella Martins Fazzito
Jan 18, 2012·Multiple Sclerosis : Clinical and Laboratory Research·G GiovannoniE Waubant
May 14, 2010·The Cochrane Database of Systematic Reviews·Loredana La MantiaRoberta Lovati
Aug 28, 2020·Arquivos de neuro-psiquiatria·Marcos MoreiraLuiz Domingos Mendes Melges

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

© 2022 Meta ULC. All rights reserved